These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35560249)

  • 1. Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer's global safety database.
    Mahadevan U; Naureckas S; Tikhonov I; Wang Y; Lin CB; Geldhof A; van der Woude CJ
    Aliment Pharmacol Ther; 2022 Aug; 56(3):477-490. PubMed ID: 35560249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure to Infliximab During Pregnancy: Post-Marketing Experience.
    Geldhof A; Slater J; Clark M; Chandran U; Coppola D
    Drug Saf; 2020 Feb; 43(2):147-161. PubMed ID: 31677004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ustekinumab Exposure in Pregnant Women From Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up To 5 Years in Crohn's Disease and 2 Years in Ulcerative Colitis.
    Abraham BP; Ott E; Busse C; Murphy C; Miller L; Baumgart DC; Scherl E; Gasink C
    Crohns Colitis 360; 2022 Jul; 4(3):otac025. PubMed ID: 36777422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry.
    Hellwig K; Geissbuehler Y; Sabidó M; Popescu C; Adamo A; Klinger J; Ornoy A; Huppke P;
    J Neurol; 2020 Jun; 267(6):1715-1723. PubMed ID: 32100126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study.
    Mitrova K; Pipek B; Bortlik M; Bouchner L; Brezina J; Douda T; Drasar T; Klvana P; Kohout P; Leksa V; Minarikova P; Novotny A; Svoboda P; Skorpik J; Ulbrych J; Veinfurt M; Zborilova B; Lukas M; Duricova D;
    J Crohns Colitis; 2022 Dec; 16(12):1808-1815. PubMed ID: 35708729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin.
    Pollack PS; Shields KE; Burnett DM; Osborne MJ; Cunningham ML; Stepanavage ME
    Birth Defects Res A Clin Mol Teratol; 2005 Nov; 73(11):888-96. PubMed ID: 16163683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data.
    Hoeltzenbein M; Beck E; Rajwanshi R; Gøtestam Skorpen C; Berber E; Schaefer C; Østensen M
    Semin Arthritis Rheum; 2016 Oct; 46(2):238-245. PubMed ID: 27346577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.
    Friend S; Richman S; Bloomgren G; Cristiano LM; Wenten M
    BMC Neurol; 2016 Aug; 16(1):150. PubMed ID: 27552976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
    Wils P; Seksik P; Stefanescu C; Nancey S; Allez M; Pineton de Chambrun G; Altwegg R; Gilletta C; Vuitton L; Viennot S; Serrero M; Fumery M; Savoye G; Collins M; Goutorbe F; Brixi H; Bouguen G; Tavernier N; Boualit M; Amiot A; Abitbol V; Laharie D; Pariente B;
    Aliment Pharmacol Ther; 2021 Feb; 53(4):460-470. PubMed ID: 33345331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy outcomes following exposure to abatacept during pregnancy.
    Kumar M; Ray L; Vemuri S; Simon TA
    Semin Arthritis Rheum; 2015 Dec; 45(3):351-6. PubMed ID: 26210783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
    Giovannoni G; Galazka A; Schick R; Leist T; Comi G; Montalban X; Damian D; Dangond F; Cook S
    Drug Saf; 2020 Jul; 43(7):635-643. PubMed ID: 32447743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy outcomes following exposure to onabotulinumtoxinA.
    Brin MF; Kirby RS; Slavotinek A; Miller-Messana MA; Parker L; Yushmanova I; Yang H
    Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):179-87. PubMed ID: 26635276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.
    Clowse MEB; Scheuerle AE; Chambers C; Afzali A; Kimball AB; Cush JJ; Cooney M; Shaughnessy L; Vanderkelen M; Förger F
    Arthritis Rheumatol; 2018 Sep; 70(9):1399-1407. PubMed ID: 29623679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes.
    Coppola D; Russo LJ; Kwarta RF; Varughese R; Schmider J
    Drug Saf; 2007; 30(3):247-64. PubMed ID: 17343431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies.
    Bérard A; Sheehy O; Zhao JP; Gorgui J; Bernatsky S; de Moura CS; Abrahamowicz M
    CMAJ; 2019 Feb; 191(7):E179-E187. PubMed ID: 30782643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Kimball AB; Guenther L; Kalia S; de Jong EMGJ; Lafferty KP; Chen DY; Langholff W; Shear NH
    JAMA Dermatol; 2021 Mar; 157(3):301-306. PubMed ID: 33533924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of cetirizine in pregnancy.
    Golembesky A; Cooney M; Boev R; Schlit AF; Bentz JWG
    J Obstet Gynaecol; 2018 Oct; 38(7):940-945. PubMed ID: 29565188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes.
    Djulus J; Koren G; Einarson TR; Wilton L; Shakir S; Diav-Citrin O; Kennedy D; Voyer Lavigne S; De Santis M; Einarson A
    J Clin Psychiatry; 2006 Aug; 67(8):1280-4. PubMed ID: 16965209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abacavir and lamivudine exposures during pregnancy and non-defect adverse pregnancy outcomes: data from the antiretroviral pregnancy registry.
    Vannappagari V; Koram N; Albano J; Tilson H; Gee C
    J Acquir Immune Defic Syndr; 2015 Mar; 68(3):359-64. PubMed ID: 25469525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study.
    McKenna K; Koren G; Tetelbaum M; Wilton L; Shakir S; Diav-Citrin O; Levinson A; Zipursky RB; Einarson A
    J Clin Psychiatry; 2005 Apr; 66(4):444-9; quiz 546. PubMed ID: 15816786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.